Vistagen Therapeutics, Inc.
$0.61
▼
-2.33%
2026-04-21 10:11:01
www.vistagen.com
NCM: VTGN
Explore Vistagen Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$24.12 M
Current Price
$0.61
52W High / Low
$5.14 / $0.43
Stock P/E
—
Book Value
$1.28
Dividend Yield
—
ROCE
-78.03%
ROE
-1.02%
Face Value
—
EPS
$-1.92
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
59
Beta
0.33
Debt / Equity
2.8
Current Ratio
4.67
Quick Ratio
6.51
Forward P/E
-0.49
Price / Sales
28.14
Enterprise Value
$-38.14 M
EV / EBITDA
0.55
EV / Revenue
-48.34
Rating
None
Target Price
$0.97
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BridgeBio Oncology Therapeutics, Inc. | $9.26 | 158.62 | $748.31 M | — | -35.28% | -48.23% | $14.87 / $8.08 | $5.14 |
| 2. | Fortrea Holdings Inc. | $10.44 | — | $976.14 M | — | -1.7% | -1.02% | $18.67 / $3.97 | $6.05 |
| 3. | Propanc Biopharma, Inc. | $0.12 | — | $2.33 M | — | -407.57% | -18.12% | $11 / $0.1 | $0.78 |
| 4. | Precision BioSciences, Inc. | $7.58 | — | $187.43 M | — | -35.84% | -62.71% | $8.82 / $3.53 | $3.83 |
| 5. | MAIA Biotechnology, Inc. | $1.41 | — | $81.91 M | — | -618.06% | -7.45% | $3.19 / $0.87 | $0.06 |
| 6. | Silexion Therapeutics Corp | $1.08 | — | $3.63 M | — | -260.98% | 1718.9% | $22.36 / $0.97 | $0.83 |
| 7. | XBiotech Inc. | $2.51 | — | $78.32 M | — | -39.17% | -28.23% | $3.61 / $2.09 | $4.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.3 M | 0.26 M | 0.24 M | -0.01 M | 0.23 M | — |
| Operating Profit | -19.55 M | -20.05 M | -15.8 M | -14.49 M | -15.12 M | — |
| Net Profit | -18.9 M | -19.42 M | -15.1 M | -13.63 M | -14.09 M | — |
| EPS in Rs | -0.48 | -0.49 | -0.38 | -0.34 | -0.36 | -0.42 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.49 M | 1.06 M | -0.23 M | 1.11 M |
| Operating Profit | -55.97 M | -33.02 M | -59.27 M | -47.55 M |
| Net Profit | -51.42 M | -29.36 M | -59.25 M | -47.76 M |
| EPS in Rs | -1.3 | -0.74 | -1.5 | -1.21 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 84.34 M | 123.65 M | 21.09 M | 74.64 M |
| Total Liabilities | 13.95 M | 9.37 M | 9.01 M | 9.93 M |
| Equity | 70.39 M | 114.29 M | 12.08 M | 64.72 M |
| Current Assets | 82.08 M | 120.67 M | 17.51 M | 71 M |
| Current Liabilities | 12.61 M | 5.12 M | 4.57 M | 5.77 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -42.1 M | -25.81 M | -49.72 M | -45.26 M |
| Investing CF | -13.15 M | -0.06 M | -0.74 M | -0.2 M |
| Financing CF | 3.21 M | 128.4 M | -1.04 M | 10.48 M |
| Free CF | -42.29 M | -25.87 M | -49.93 M | -45.46 M |
| Capex | -0.19 M | -0.06 M | -0.21 M | -0.2 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -54.32% | 568.72% | -120.47% | — |
| Earnings Growth % | -75.12% | 50.44% | -24.05% | — |
| Profit Margin % | -10579.84% | -2759.59% | 26100.44% | -4307.19% |
| Operating Margin % | -11517.08% | -3103.48% | 26109.25% | -4287.75% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -11386.42% | -3050.09% | 25874.89% | -4242.75% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-06-07 | 1:0.0333333 |